News Category
Kairos Pharma Ltd. plans to acquire worldwide rights to a Phase 1-ready oral c-MET kinase inhibitor, expanding its oncology pipeline and advancing cli...
Kairos Pharma Ltd. has signed a term sheet to acquire worldwide rights to two non-small cell lung cancer assets, a pre-IND EGFR inhibitor and a Phase ...
TransCode Therapeutics appointed Jack E. Stover to its Board of Directors, adding over 30 years of life sciences executive experience as the company a...
